Inspire Medical Systems (NYSE:INSP) Updates FY 2025 Earnings Guidance

Key Points

• Inspire Medical Systems updated its FY 2025 earnings guidance, predicting an EPS range of 0.400-0.500, significantly lower than the consensus estimate of 2.267.
• The company also issued revenue guidance between $900.0 million and $910.0 million, compared to the consensus estimate of $949.4 million.
• Shares of Inspire Medical Systems saw significant trading activity, closing at $130.79 on Monday, influenced by a market capitalization of $3.86 billion and target price revisions from multiple analysts.

Inspire Medical Systems (NYSE:INSP - Get Free Report) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided EPS guidance of 0.400-0.500 for the period, compared to the consensus EPS estimate of 2.267. The company issued revenue guidance of $900.0 million-$910.0 million, compared to the consensus revenue estimate of $949.4 million.

Inspire Medical Systems Stock Performance

Shares of Inspire Medical Systems stock traded up $4.69 during trading on Monday, hitting $130.79. 1,376,548 shares of the company's stock were exchanged, compared to its average volume of 551,122. Inspire Medical Systems has a 52-week low of $123.25 and a 52-week high of $225.00. The business has a 50-day simple moving average of $131.78 and a 200-day simple moving average of $154.63. The stock has a market capitalization of $3.86 billion, a price-to-earnings ratio of 60.27, a PEG ratio of 1.93 and a beta of 1.22.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $0.45 EPS for the quarter, topping analysts' consensus estimates of $0.22 by $0.23. Inspire Medical Systems had a net margin of 7.92% and a return on equity of 10.00%. On average, equities analysts anticipate that Inspire Medical Systems will post 2.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley reduced their price target on shares of Inspire Medical Systems from $200.00 to $182.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 15th. JPMorgan Chase & Co. reduced their price target on shares of Inspire Medical Systems from $235.00 to $195.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. KeyCorp reduced their price target on shares of Inspire Medical Systems from $216.00 to $197.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 22nd. Wells Fargo & Company reduced their price target on shares of Inspire Medical Systems from $195.00 to $174.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Finally, Stifel Nicolaus reduced their price target on shares of Inspire Medical Systems from $190.00 to $175.00 and set a "hold" rating on the stock in a research note on Monday, April 21st. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $208.55.

Institutional Investors Weigh In On Inspire Medical Systems

A number of large investors have recently modified their holdings of INSP. Goldman Sachs Group Inc. boosted its holdings in shares of Inspire Medical Systems by 57.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company's stock valued at $8,190,000 after buying an additional 18,857 shares in the last quarter. Royal Bank of Canada increased its holdings in shares of Inspire Medical Systems by 16.0% in the 1st quarter. Royal Bank of Canada now owns 32,769 shares of the company's stock valued at $5,220,000 after purchasing an additional 4,528 shares in the last quarter. Finally, Integrated Wealth Concepts LLC purchased a new position in shares of Inspire Medical Systems in the 1st quarter valued at about $524,000. 94.91% of the stock is owned by hedge funds and other institutional investors.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.